Ponatinib (AP24534) is a imidazopyridine-based pan-inhibitor of the kinases Abl, Abl(T315I), and other clinically important Abl kinase domain mutants at potencies of 0.37 nM, 2.0 nM, and 0.30-0.44 nM, respectively. Ponatinib also potently inhibits Src, VEGFR, FGFR, and PDGFR at 5.4, 1.5, 22, and 1.1 nM, respectively, while being >1000-fold selective over IGF-1R, Aurora A, andCDK2/Cyclin E. [1] In contrast to first- (imatinib) and second-line therapies (nilotinib, dasatinib) for CML, Ponatinib shows inhibition against the T31I mutant of Bcr-Abl.In a panel of leukemic cell lines containing activating mutations in Flt3, Kit, or activating fusions of FGFR, PDGFRa, EOL1, and KG-1, Ponatinib inhibited phosphorylation of all four receptor tyrosine kinases in a dose dependent manner with IC50 values between 0.3 and 20 nM. [2] Apoptotic induction is believed to be the mechanism by which Ponatinib inhibits FLT3-ITD to in turn inhibit MV4-11 cell viability. [2]

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。